PMID int64 2.09k 36.2M | Title stringlengths 21 414 | Abstract stringlengths 175 8.83k | Hypothesis stringclasses 14
values | Entailment float64 0 1 | Positive bool 2
classes | Label_idx int64 1 7 |
|---|---|---|---|---|---|---|
26,200,040 | Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. | Medullary thyroid cancer (MTC)-related diarrhea can be debilitating, reduces quality of life (QOL), and may be the only indication for initiating systemic therapy. Conventional antidiarrheal drugs are not always helpful and may have side effects. Calcium aluminosilicate antidiarrheal (CASAD), a natural calcium montmorr... | This study has a control, double-blind, or comparison patient group | 0 | true | 7 |
26,200,040 | Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. | Medullary thyroid cancer (MTC)-related diarrhea can be debilitating, reduces quality of life (QOL), and may be the only indication for initiating systemic therapy. Conventional antidiarrheal drugs are not always helpful and may have side effects. Calcium aluminosilicate antidiarrheal (CASAD), a natural calcium montmorr... | This study does not have any comparison patient group | 1 | false | 7 |
26,200,040 | Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. | Medullary thyroid cancer (MTC)-related diarrhea can be debilitating, reduces quality of life (QOL), and may be the only indication for initiating systemic therapy. Conventional antidiarrheal drugs are not always helpful and may have side effects. Calcium aluminosilicate antidiarrheal (CASAD), a natural calcium montmorr... | This study has human subjects | 1 | true | 1 |
26,200,040 | Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. | Medullary thyroid cancer (MTC)-related diarrhea can be debilitating, reduces quality of life (QOL), and may be the only indication for initiating systemic therapy. Conventional antidiarrheal drugs are not always helpful and may have side effects. Calcium aluminosilicate antidiarrheal (CASAD), a natural calcium montmorr... | This study does not have human subjects | 0 | false | 1 |
26,200,040 | Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. | Medullary thyroid cancer (MTC)-related diarrhea can be debilitating, reduces quality of life (QOL), and may be the only indication for initiating systemic therapy. Conventional antidiarrheal drugs are not always helpful and may have side effects. Calcium aluminosilicate antidiarrheal (CASAD), a natural calcium montmorr... | This study contains population size or sample size information | 1 | true | 6 |
26,200,040 | Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. | Medullary thyroid cancer (MTC)-related diarrhea can be debilitating, reduces quality of life (QOL), and may be the only indication for initiating systemic therapy. Conventional antidiarrheal drugs are not always helpful and may have side effects. Calcium aluminosilicate antidiarrheal (CASAD), a natural calcium montmorr... | This study does not contain population size information | 0 | false | 6 |
26,200,040 | Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. | Medullary thyroid cancer (MTC)-related diarrhea can be debilitating, reduces quality of life (QOL), and may be the only indication for initiating systemic therapy. Conventional antidiarrheal drugs are not always helpful and may have side effects. Calcium aluminosilicate antidiarrheal (CASAD), a natural calcium montmorr... | This study has quantitative outcomes like numbers, P-value, OR, CI, HR, RR, or patient ratios | 1 | true | 4 |
26,200,040 | Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. | Medullary thyroid cancer (MTC)-related diarrhea can be debilitating, reduces quality of life (QOL), and may be the only indication for initiating systemic therapy. Conventional antidiarrheal drugs are not always helpful and may have side effects. Calcium aluminosilicate antidiarrheal (CASAD), a natural calcium montmorr... | This study does not have any quantitative outcomes | 0 | false | 4 |
26,200,040 | Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. | Medullary thyroid cancer (MTC)-related diarrhea can be debilitating, reduces quality of life (QOL), and may be the only indication for initiating systemic therapy. Conventional antidiarrheal drugs are not always helpful and may have side effects. Calcium aluminosilicate antidiarrheal (CASAD), a natural calcium montmorr... | This study has a target drug | 1 | true | 5 |
26,200,040 | Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. | Medullary thyroid cancer (MTC)-related diarrhea can be debilitating, reduces quality of life (QOL), and may be the only indication for initiating systemic therapy. Conventional antidiarrheal drugs are not always helpful and may have side effects. Calcium aluminosilicate antidiarrheal (CASAD), a natural calcium montmorr... | This study does not have a target drug | 0 | false | 5 |
26,200,040 | Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. | Medullary thyroid cancer (MTC)-related diarrhea can be debilitating, reduces quality of life (QOL), and may be the only indication for initiating systemic therapy. Conventional antidiarrheal drugs are not always helpful and may have side effects. Calcium aluminosilicate antidiarrheal (CASAD), a natural calcium montmorr... | This study has a target disease | 1 | true | 2 |
26,200,040 | Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. | Medullary thyroid cancer (MTC)-related diarrhea can be debilitating, reduces quality of life (QOL), and may be the only indication for initiating systemic therapy. Conventional antidiarrheal drugs are not always helpful and may have side effects. Calcium aluminosilicate antidiarrheal (CASAD), a natural calcium montmorr... | This study does not have a target disease | 0 | false | 2 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study has a cohort study or clinical trial | 1 | true | 3 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study does not have any cohorts or clinical trial | 0 | false | 3 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study has a control, double-blind, or comparison patient group | 1 | true | 7 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study does not have any comparison patient group | 0 | false | 7 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study has human subjects | 1 | true | 1 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study does not have human subjects | 0 | false | 1 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study contains population size or sample size information | 1 | true | 6 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study does not contain population size information | 0 | false | 6 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study has quantitative outcomes like numbers, P-value, OR, CI, HR, RR, or patient ratios | 0 | true | 4 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study does not have any quantitative outcomes | 1 | false | 4 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study has a target drug | 1 | true | 5 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study does not have a target drug | 0 | false | 5 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study has a target disease | 1 | true | 2 |
32,907,638 | Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. | The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use... | This study does not have a target disease | 0 | false | 2 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study has a cohort study or clinical trial | 1 | true | 3 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study does not have any cohorts or clinical trial | 0 | false | 3 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study has a control, double-blind, or comparison patient group | 1 | true | 7 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study does not have any comparison patient group | 0 | false | 7 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study has human subjects | 1 | true | 1 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study does not have human subjects | 0 | false | 1 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study contains population size or sample size information | 1 | true | 6 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study does not contain population size information | 0 | false | 6 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study has quantitative outcomes like numbers, P-value, OR, CI, HR, RR, or patient ratios | 1 | true | 4 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study does not have any quantitative outcomes | 0 | false | 4 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study has a target drug | 1 | true | 5 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study does not have a target drug | 0 | false | 5 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study has a target disease | 1 | true | 2 |
35,187,850 | Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. | Adriamycin, bleomycin, vinblastine, dacarbazine (ABVD), the de facto standard of care in adult-onset Hodgkin lymphoma (HL), has not been directly compared to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), a pediatric-aimed regimen designed to reduce late effects. We aimed to... | This study does not have a target disease | 0 | false | 2 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study has a cohort study or clinical trial | 1 | true | 3 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study does not have any cohorts or clinical trial | 0 | false | 3 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study has a control, double-blind, or comparison patient group | 0 | true | 7 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study does not have any comparison patient group | 1 | false | 7 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study has human subjects | 1 | true | 1 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study does not have human subjects | 0 | false | 1 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study contains population size or sample size information | 1 | true | 6 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study does not contain population size information | 0 | false | 6 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study has quantitative outcomes like numbers, P-value, OR, CI, HR, RR, or patient ratios | 1 | true | 4 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study does not have any quantitative outcomes | 0 | false | 4 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study has a target drug | 1 | true | 5 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study does not have a target drug | 0 | false | 5 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study has a target disease | 1 | true | 2 |
11,493,229 | Gabapentin in the treatment of hemifacial spasm. | To evaluate the efficacy of gabapentin in the treatment of hemifacial spasm. Twenty-three patients with hemifacial spasm not suitable for surgery or therapy with botulinum toxin were treated with gabapentin. The main efficacy parameter was the percentage of spasm reduction. A clinically significant reduction of spasms ... | This study does not have a target disease | 0 | false | 2 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study has a cohort study or clinical trial | 0 | true | 3 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study does not have any cohorts or clinical trial | 1 | false | 3 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study has a control, double-blind, or comparison patient group | 0 | true | 7 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study does not have any comparison patient group | 1 | false | 7 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study has human subjects | 1 | true | 1 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study does not have human subjects | 0 | false | 1 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study contains population size or sample size information | 0 | true | 6 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study does not contain population size information | 1 | false | 6 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study has quantitative outcomes like numbers, P-value, OR, CI, HR, RR, or patient ratios | 0 | true | 4 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study does not have any quantitative outcomes | 1 | false | 4 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study has a target drug | 1 | true | 5 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study does not have a target drug | 0 | false | 5 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study has a target disease | 1 | true | 2 |
6,135,344 | Beta blockers in ischemic heart disease. | Many trials have reported that beta blockers increase survival after myocardial infarction; these trials are reviewed. The timolol trial was randomized and showed that mortality was reduced for all patients randomized to beta blockers. Similar findings have been found in both the metoprolol trial in Göteburg and the Be... | This study does not have a target disease | 0 | false | 2 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study has a cohort study or clinical trial | 1 | true | 3 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study does not have any cohorts or clinical trial | 0 | false | 3 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study has a control, double-blind, or comparison patient group | 1 | true | 7 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study does not have any comparison patient group | 0 | false | 7 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study has human subjects | 1 | true | 1 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study does not have human subjects | 0 | false | 1 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study contains population size or sample size information | 1 | true | 6 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study does not contain population size information | 0 | false | 6 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study has quantitative outcomes like numbers, P-value, OR, CI, HR, RR, or patient ratios | 0 | true | 4 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study does not have any quantitative outcomes | 1 | false | 4 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study has a target drug | 1 | true | 5 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study does not have a target drug | 0 | false | 5 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study has a target disease | 1 | true | 2 |
11,314,873 | Administration of citalopram before ECT: seizure duration and hormone responses. | From theoretical and clinical perspectives, it is important to know if selected serotonin-reuptake inhibitors (SSRIs), often administered concurrently with electroconvulsive therapy (ECT), modify seizure duration. In a study with a double-blind, cross-over design, the authors evaluated the effect of citalopram, the mos... | This study does not have a target disease | 0 | false | 2 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study has a cohort study or clinical trial | 1 | true | 3 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study does not have any cohorts or clinical trial | 0 | false | 3 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study has a control, double-blind, or comparison patient group | 0 | true | 7 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study does not have any comparison patient group | 1 | false | 7 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study has human subjects | 0 | true | 1 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study does not have human subjects | 1 | false | 1 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study contains population size or sample size information | 1 | true | 6 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study does not contain population size information | 0 | false | 6 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study has quantitative outcomes like numbers, P-value, OR, CI, HR, RR, or patient ratios | 1 | true | 4 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study does not have any quantitative outcomes | 0 | false | 4 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study has a target drug | 1 | true | 5 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study does not have a target drug | 0 | false | 5 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study has a target disease | 1 | true | 2 |
25,351,232 | Feline urinary tract pathogens: prevalence of bacterial species and antimicrobial resistance over a 10-year period. | The purpose of this retrospective study was to identify bacterial species in cats with bacterial urinary tract infections (UTIs) and to investigate their antimicrobial susceptibilities over a 10-year period. Three hundred and thirty cultures from 280 cats were included in the study. The mean age of affected cats was 9.... | This study does not have a target disease | 0 | false | 2 |
15,567,458 | The difference between clopidogrel responsiveness and posttreatment platelet reactivity. | Aggregation is the most common measure of platelet reactivity. The relative inhibition of platelet aggregation between pretreatment and posttreatment is the most common estimate of clopidogrel responsiveness. However, patients responsive to clopidogrel may remain with highly reactive platelets and thus have increased t... | This study has a cohort study or clinical trial | 1 | true | 3 |
15,567,458 | The difference between clopidogrel responsiveness and posttreatment platelet reactivity. | Aggregation is the most common measure of platelet reactivity. The relative inhibition of platelet aggregation between pretreatment and posttreatment is the most common estimate of clopidogrel responsiveness. However, patients responsive to clopidogrel may remain with highly reactive platelets and thus have increased t... | This study does not have any cohorts or clinical trial | 0 | false | 3 |
15,567,458 | The difference between clopidogrel responsiveness and posttreatment platelet reactivity. | Aggregation is the most common measure of platelet reactivity. The relative inhibition of platelet aggregation between pretreatment and posttreatment is the most common estimate of clopidogrel responsiveness. However, patients responsive to clopidogrel may remain with highly reactive platelets and thus have increased t... | This study has a control, double-blind, or comparison patient group | 0 | true | 7 |
15,567,458 | The difference between clopidogrel responsiveness and posttreatment platelet reactivity. | Aggregation is the most common measure of platelet reactivity. The relative inhibition of platelet aggregation between pretreatment and posttreatment is the most common estimate of clopidogrel responsiveness. However, patients responsive to clopidogrel may remain with highly reactive platelets and thus have increased t... | This study does not have any comparison patient group | 1 | false | 7 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.